Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where David Winkler is active.

Publication


Featured researches published by David Winkler.


Journal of Biological Chemistry | 1997

Identification and Characterization of Mutations in Ha-Ras That Selectively Decrease Binding to cRaf-1

David Winkler; Jeffrey C. Johnson; Jonathan A. Cooper; Anne B. Vojtek

The oncoprotein Ras transforms cells by binding to one or more effector proteins. Effector proteins have been identified by their ability to bind to Ras in the GTP but not GDP form, and by their requirement for the Ras effector domain for binding. The best understood Ras effectors are serine/threonine kinases of the Raf family, but other candidate Ras effectors, including a Ral guanine nucleotide dissociation stimulator and phosphatidylinositol 3-kinase (PI3 kinase) have also been identified. To investigate the mechanism of binding of cRaf-1 to Ras, and to investigate the roles of other candidate Ras effectors in transformation, we have isolated and characterized mutants of activated Ras with decreased binding to cRaf-1 relative to other candidate effectors. Examination of these mutants indicates that surface-exposed residues of Ras outside the minimal effector domain interact differentially with cRaf-1 and other Ras-binding proteins, and that fibroblast transformation correlates with cRaf-1 binding and mitogen-activated protein (MAP) kinase activation. Furthermore, activation of PI3 kinase can occur in the absence of significant MAP kinase activation, suggesting that PI3 kinase activation is a primary effect of Ras.


Journal of Biological Chemistry | 2005

Sclerostin inhibition of wnt-3a-induced C3H10T1/2 cell differentiation is indirect and mediated by bone morphogenetic proteins

David Winkler; May Kung Sutherland; Ethan W. Ojala; Eileen Turcott; James C. Geoghegan; Diana Shpektor; John E. Skonier; Changpu Yu; John Latham


Journal of Biological Chemistry | 2004

Noggin and Sclerostin Bone Morphogenetic Protein Antagonists Form a Mutually Inhibitory Complex

David Winkler; Changpu Yu; James C. Geoghegan; Ethan W. Ojala; John E. Skonier; Diana Shpektor; May Kung Sutherland; John Latham


Archive | 2004

Antibodies specific for sclerostin and methods of screening and use therefor

David Winkler; Jiye Shi; John Latham


Archive | 2006

Antibodies specific for sclerostin

David Winkler; Jiye Shi; John Latham


Archive | 2004

Ligands for tgf-beta binding proteins and uses thereof

David Winkler; John Latham; John E. Skonier; Diana Shpektor; Trenton Hayes; James C. Geoghegan


Archive | 2010

Antibody specific for sclerostin and method for increasing bone mineralization

John Latham; Jiye Shi; David Winkler; デーヴィッド ジー. ウィンクラー,; ジイエ シャイ; ジョン レーサム


Archive | 2007

Anti human sclerostin antibodies

John Latham; David Winkler


Archive | 2007

Anticorps et diagnostics

John Latham; David Winkler


Archive | 2006

Agents de fixation

Christopher Paszty; Martyn Kim Robinson; Kevin Graham; Alistair J. Henry; Kelly Sue Hoffmann; John Latham; Alastair David Griffiths Lawson; Hsieng S. Lu; Andy Popplewell; Wenyan Shen; David Winkler; Aaron George Winters

Collaboration


Dive into the David Winkler's collaboration.

Researchain Logo
Decentralizing Knowledge